Loading patent…
AssigneeThe Trustees of Columbia University in the City of New York
InventorWei Gu
Estimating the term…
A novel complex is identified between the NAD-dependent deacetylase, SIRT1 and its novel inhibitor, DBC1. Provided herein are methods to indentify a compound that inhibits the complexation between SIRT1 and DBC1. Exemplary methods comprise contacting either the complexation between DBC1 and SIRT1 with an agent being tested for its ability to inhibit the complexation between SIRT1 and DBC1. Also, provided are methods to identify a compound that increases the complexation between SIRT1 and DBC1. Exemplary methods comprise contacting either the complexation between DBC1 and SIRT1 with an agent being tested for its ability to increase the complexation between SIRT1 and DBC1. Further, methods are provided to increase or decrease SIRT1 activity by contacting the complexation between SIRT1 and DBC1 with a peptide that either decreases or increases the complexation between SIRT1 and DBC1. Further, methods are provided for the treatment of patients suffering from diseases including metabolic diseases including obesity and diabetes, and neurodegenerative disorders including Alzheimer's disease and Huntington's disease using compounds that inhibit the complexation between SIRT1 and DBC1.
1-2. (canceled)
A method for identifying a compound which inhibits the complexation between DBC1 and SIRT1 comprising:
A method for identifying a compound which increases the complexation between DBC1 and SIRT1 comprising:
A method for increasing SIRT1 activity by contacting the complexation between SIRT1 and DBC1 with an agent which inhibits DBC1 activity.
29-33. (canceled)
Dependencies are inferred from the claim text.